Clinuvel Analyses From U.S. Study Show ‘Dramatic Improvement’
By Malcolm Scott -
2011-11-03T08:18:08Z
Clinuvel Pharmaceuticals Ltd. (CUV) said analyses of its Phase II U.S. study in EPP has shown patients who recieved the active drug were able to spend more time in direct sunlight.
To contact the editor responsible for this story: Malcolm Scott at mscott23@bloomberg.net
Rate this Page